Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Deffered Revenue: 2010

  • Heron Therapeutics' Non-Current Deffered Revenue was N/A to $35,000 in Q4 2010 from the same period last year, while for Dec 2010 it was $35,000, marking a year-over-year change of. This contributed to the annual value of $35,000 for FY2010, which is N/A change from last year.
  • Per Heron Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $35,000 for Q4 2010.
  • Heron Therapeutics' 5-year Non-Current Deffered Revenue high stood at $35,000 for Q4 2010, and its period low was $35,000 during Q4 2010.
  • Moreover, its 1-year median value for Non-Current Deffered Revenue was $35,000 (2010), whereas its average is $35,000.